Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies

a degenerative pathology and ligand technology, applied in the field of ligands for the diagnosis of degenerative pathologies, can solve the problems of complex preparation and purification of antibody-based imaging agents, preventing industrial development and commercialization, and achieving high affinity, specificity and/or selectivity for selectins, excellent sensitivity, and high sensitivity

Inactive Publication Date: 2012-07-19
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, they exhibit several disadvantages that will certainly preclude their industrial development and commercialization.
Indeed, the preparation and purification of sialyl Lewis X-based imaging agents and of antibody-based imaging agents is complex and very costly.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies
  • Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies
  • Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies

Examples

Experimental program
Comparison scheme
Effect test

example 1

LMW Fucoidans are Highly Specific Ligands of P-Selectin

Materials and Methods

[0125]Chemical Products. Fluorescein isothiocyanate (FITC) was purchased from Fluka (Saint-Quentin Fallavier, France); streptavidin-peroxidase conjugate from Dako (Trappes, France); diaminopropane, sodium cyanobromohydride and peroxidase substrate ABTS from Sigma-Aldrich (Saint-Quentin Fallavier, France); sinapinic acid solution from Bio-Rad Laboratories (Hercules, Calif., USA); and the amine coupling kit and running buffer from BIAcore (Uppsala, Sweden).

[0126]Polysaccharides. The low molecular weight fucoidan (based on sulfated repeating fucose unit; M=7200 g / M; SO4=30% (w / w)) was prepared from brown seaweed as previously described (A. Nardella et al., Carbohydr. Res., 1996, 289: 201-208). The low molecular weight heparin (M=5700 g / M; SO4=45% (w / w)) and low molecular weight dextran sulfate (M=8000 g / M; SO4=52% (w / w)), were supplied from Sigma-Aldrich; and the biotinylated polyacrylamide-type glycoconjugate ...

example 2

99mTc-labelled Fucoidan as P-selectin-targeted Imaging Agent for the in vivo Scintigraphic Detection of Platelet Activation and Accumulation

[0147]Fucoidan was labelled with technetium-99m (99mTc) using the well-known stannous reaction in solution. Briefly, 4 μL of stannous chloride were added to 10 μL of fucoidan (1 mg / mL, MW=7200) followed by 2 μL of potassium borohydride. Immediately after combination of these reagents, 50 μL of 99mTc (corresponding to 15-30 mCi) were gently added to the mixture. The labelling reaction was complete after 1 hour of incubation. Control of the labelling was performed using thin layer paper chromatography and methyl-ketone as eluant. The percentage of labelling was 100%.

[0148]Rat models of endocarditic vegetations, aneurysmal and atrial trombi were used as animal models of clinical conditions associated with platelet activation and fibrin formation. Intravenous injection of 1 μg of 99mTc-labelled fucoidan allowed the in vivo visualization of platelet-...

example 3

Preparation of fucoidan-coated USPIO Particles

[0150]The present Applicants have developed five different strategies to coat fucoidan onto USPIO particles.

[0151]The first strategy involves the synthesis of iron particles in the presence of unmodified fucoidan. The Applicants have applied a method of synthesis previously described with dextran (R. S. Molday et al., J. Immunol. Methods, 1982, 52: 353-367) replacing dextran MW 40000 by fucoidan MW 50500. Fucoidan-coated iron nanoparticles were obtained. However, these particles were found to be unstable in water.

[0152]The second strategy comprises the coating of an acidic ferrofluid with unmodified fucoidan. Fucoidan was incubated with acidic ferrofluid. Fucoidan-coated iron nanoparticles were obtained that were stable in aqueous medium pH 7.4, but unstable in buffers with ionic strength of 0.15 M, which are used in most applications. The synthesis could be obtained in the presence of a cross-linker (A. San Juan et al., J. Biomed. Mater...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention relates to the diagnosis of clinical conditions characterized by undesirable and / or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia / reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.

Description

RELATED APPLICATION[0001]The present patent application is a continuation-in-part of patent application Ser. No. 13 / 259,802, which was itself filed pursuant to 35 U.S.C. §371 as a U.S. National Phase application of International Patent Application No. PCT / IB32009 / 052791 filed on Apr. 10, 2009. The entire content of the PCT application and of the U.S. National Phase application is incorporated herein by reference in its entirety. BACKGROUND OF THE INVENTION[0002]Numerous human degenerative diseases, including cardiovascular degenerative diseases, but also organ-specific degenerative diseases, involve circulating cell / vascular wall interactions. Selectins are important cell adhesion molecules, with high affinities for carbohydrate moieties. They play a prominent and critical role in the initial stages of circulating cellular components and vascular wall interactions by mediating leucocytes / platelet and leucocytes / endothelium interactions. Three types of selectins have been discovered ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K49/00G01N33/53C07H1/00
CPCA61K49/0438G01N33/53A61K49/221A61K49/223A61K51/065G01N33/574G01N33/6893G01N33/6896G01N2333/405G01N2333/4724G01N2400/00G01N2800/102G01N2800/28G01N2800/32C08B37/0063C08L5/00A61K49/04A61K49/06A61K49/22A61K51/00A61K49/1863
Inventor MICHEL, JEAN-BAPTISTELETOURNEUR, DIDIERCHAUBET, FREDERICBACHELET, LAUREROUZET, FRANCOISMEULEMANS, ALAIN
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap